000			01731cam a2200421 i 4500
001			ocn956436504
003			OCoLC
005			20170826160830.0
006			m o d f
007			cr mn|||||||||
008			160810s2010 dcuab ob f000 0 eng c
040			_aGPO _beng _erda _epn _cGPO _dGPO
042			_apcc
043			_an-us---
074			_a0445-B-07 (online)
086	0		_aHE 1.75:OEI-01-08-00510
088			_aOEI-01-08-00510
099			_aHE 1.75:OEI-01-08-00510
110	1		_aUnited States. _bDepartment of Health and Human Services. _bOffice of Inspector General, _eauthor.
245	1	0	_aChallenges to FDA's ability to monitor and inspect foreign clinical trials / _cDepartment of Health and Human Services, Office of Inspector General.
246	3		_aChallenges to Food and Drug Administration's ability to monitor and inspect foreign clinical trials
264		1	_a[Washington, D.C.] : _bDepartment of Health and Human Services, Office of Inspector General, _c2010.
300			_a1 online resource (iv, 43 pages) : _billustrations, color map
337			_2rdamedia
338			_2rdacarrier
500			_aTitle from title screen (viewed Aug 9, 2016).
500			_a"June 2010."
500			_a"OEI-01-08-00510."
500			_aCRDP Project record.
504			_aIncludes bibliographical references.
650		0	_aClinical trials _xGovernment policy _zUnited States.
650		0	_aBiologicals _xTesting _xGovernment policy _zUnited States.
650		0	_aDrugs _xTesting _xGovernment policy _zUnited States.
610	1	0	_aUnited States. _bFood and Drug Administration _xAuditing.
856	4	0	_uhttp://purl.fdlp.gov/GPO/gpo71045
949			_aBEV _bFed Docs
942			_c3
999			_c265400 _d265400